News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.
Police Fatally Shoot Another Black Male Near Ferguson
This Little Kid Is DEVASTATED When His Dad "Steals" His Ear and Nose
Should the U.S. Capitol Have a POW/MIA Memorial?
Hawaii-based pharmaceutical company Cardax is partnering with major drug capsule manufacturer Capsugel to mass-produce the anti-inflammatory nutritional supplement called astaxanthin.
Yet, if you've been a shareholder in Pfizer over the past 15 years, and didn't purchase Pfizer stock during the Great Recession, things haven't been so great from a share price perspective.
Spencer Falk, whose marketing expertise was mission-critical to the blockbuster success of Viagra and Celebrex, among other medical brands, today announced that he would lead the commercialization of early cancer detection technology for Senior Scientific, a division of Manhattan Scientifics .
According to GuruFocus list of 52-week lows , these Guru stocks have reached their 52-week lows.
The Alabama Supreme Court has reaffirmed its controversial ruling that brand-name drugmakers can be held liable for injuries caused by drugs produced by generic manufacturers.
AQR Capital Management , managed by Cliff Asness , recently published its 13F filing with the U.S. Securities and Exchange Commission for the second quarter of 2014.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer Inc .
Pfizer Inc. today announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib.
This article is a continuation of a monthly series highlighting the top net payout yield stocks that was started back in June 2012 and explained in August 2012 .
Individual investors typically produce better results when they live by a set of rules and beliefs on what to buy, hold or sell.
The Wall Street Bull Market Express is leaving the station and you have two months, maybe three to run down the platform, take the leap, and latch on to the caboose.
By now, most investors know all the problems facing pharmaceutical giant GlaxoSmithKline .
Pfizer Inc. announced today that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086 , the company's vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds.
Equities on both sides of the Atlantic advanced amid expectations that central banks will remain more accommodating than previously expected to help spur the pace of recovery and counter the impact of international conflict.
Updated: Wed Aug 20, 2014 05:43 am
Copyright © 2014 Topix LLC